BNP Paribas Asset Management
XERS icon

BNP Paribas Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

BNP Paribas Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
2,655
-450
-14% -$2.87K ﹤0.01% 2036
2026
Q1 		$18K Buy
3,105
+752
+32% +$4.99K ﹤0.01% 2071
2025
Q4 		$18K Buy
+2,353
New +$18.5K ﹤0.01% 1992

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BNP Paribas Asset Management's XERS Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Xeris Biopharma Holdings (XERS) stake by 14% in Q2 2026, selling an estimated $2.87K and leaving 2,655 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

BNP Paribas Asset Management first reported a position in XERS in Q4 2025 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • BNP Paribas Asset Management held 2,655 shares of Xeris Biopharma Holdings worth $21K as of Q2 2026.
  • BNP Paribas Asset Management sold 450 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.87K.
  • Xeris Biopharma Holdings made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2036 holding.
  • BNP Paribas Asset Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.